期刊
MEDCHEMCOMM
卷 10, 期 7, 页码 1068-1081出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c9md00018f
关键词
-
资金
- Swiss National Science Foundation [BSCGI0_157842]
- Swiss National Science Foundation (SNF) [BSCGI0_157842] Funding Source: Swiss National Science Foundation (SNF)
Peptides and small protein scaffolds are gaining increasing interest as therapeutics. Similarly to full-length antibodies, they can bind a target with a high binding affinity and specificity while remaining small enough to diffuse into tissues. However, despite their numerous advantages, small biotherapeutics often suffer from a relatively short circulating half-life, thus requiring frequent applications that ultimately restrict their ease of use and user compliance. To overcome this limitation, a large variety of half-life extension strategies have been developed in the last decades. Linkage to ligands that non-covalently bind to albumin, the most abundant serum protein with a circulating half-life of similar to 19 days in humans, represents one of the most successful approaches for the generation of long-lasting biotherapeutics with improved pharmacokinetic properties and superior efficacy in the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据